Using the same platform used for the Covid-19 vaccine, the University of Oxford has announced the start of a trial for a plague vaccine
Reminds you something of the acronym ChAdOx1? It is the name of the platform viral used for the AstraZeneca vaccine, developed together withOxford University, against the coronavirus. A technology quite similar will now come used to study a plague vaccine, disease of origin bacterial never completely eradicated. Only a year ago, in fact, we were talking about the cases of over bubbonica reported in Mongolia. But the phenomenon, although limited compared to other health problems, is much more extensive and persists in different areas of the world, especially in some zone dell’Africa e dell’Asia. There were over three thousand cases reported between 2010 and 2015 and more than 500 victims, cite from Oxford, to remember that the over it is far from a relegated past problem.
The over it is a disease caused by the bacterium Yersinia pestis. Depending on the manifestations of the disease and the manner of transmission three different types are identified (bubonic, pulmonary and septicemic, not strictly separated, remember the Higher Institute of Health). There disease you can deal with antibiotics (otherwise the fatality rates are very high) but being able to have preventive tools such as a vaccine it would be of great help, especially for hard-to-reach areas, explained Christine Rollier, associate professor of vaccinology at the Oxford Vaccine Group. It is with this intent that one was launched experimentation phase I for a plague vaccine, therefore aimed at testing the safety of the product but also at evaluating the immune responses in volunteers who will be enrolled (the plan is to include about forty, aged between 18 and 55).
The construction and operating principle of the vaccine candidate (traditionally intramuscular) are quite similar to that employed in the fight against Covid. ChAdOx1 is a viral vector, in detail one weakened version of an adenovirus coming from chimpanzees, unable to replicate in humans. On this platform, gods have been inserted geni that they code for proteins of the bacterium over (the F1 and V antigens). With the same principle of the product against the coronavirus once in the host the production of these antigens will theoretically prepare a immune response useful to fight the bacterium and the infection in case of exposure (here all the details of the experimentation).